Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Generalised Social Anxiety Disorder
NCT00302770Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing Quetiapine with Placebo (2 arms). Primary endpoint: Change on Lebowitz Social Anxiety Scale from baseline to endpoint. Started Jun 2006; status: terminated.
02
Drugs
quetiapine
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00302770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302770.